NCT06779539 is a Phase 2 clinical trial of Ensartinib in Non-Small Cell Lung Cancer, sponsored by West China Hospital.

Who is sponsoring NCT06779539?

NCT06779539 is sponsored by West China Hospital.

What drugs are being tested in NCT06779539?

Interventions in NCT06779539: Ensartinib.

What condition does NCT06779539 study?

NCT06779539 studies Non-Small Cell Lung Cancer.

Is NCT06779539 still recruiting?

NCT06779539 is currently not yet recruiting. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT06779539

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Not yet recruiting Phase 2 Last updated 17 January 2025

What this trial tests

Phase 2 trial testing Ensartinib in Non-Small Cell Lung Cancer in 33 participants. Not yet recruiting.

Timeline

15 January 2025

Primary endpoint
12 June 2028

12 December 2030

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	15 January 2025
Primary completion	12 June 2028
Estimated completion	12 December 2030

Drugs / interventions tested

Ensartinib (ENSARTINIB) — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

West China Hospital

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-arm, prospective, multicenter, phase II study is designed to evaluate the efficacy and safety of ensartinib as neoadjuvant treatment in ALK positive, resectable for stage II to III non-small cell lung cancer patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.
Voruganti T, Marar R, Bleiberg B, Garbo E, et al · · 2025 · cited 2× · PMID 40311093 · DOI 10.1200/edbk-25-472804
Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives.
Koutoukoglou P, Mountzios G. · · 2026 · PMID 41681965 · DOI 10.3390/cancers18030493
A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer.
Khan SR, Kotrri E, Breadner D, Kundapur V, et al · · 2025 · PMID 41590340 · DOI 10.3390/curroncol33010020

Verify or expand the search:

Other trials of Ensartinib

Trials testing the same drug.

NCT07448116 — Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. · Phase 1, PHASE2 · recruiting
NCT06762327 — Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer · Phase 2 · not yet recruiting
NCT06785584 — Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Pos · Phase 4 · not yet recruiting
NCT06780839 — Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD · Phase 2 · not yet recruiting
NCT06563999 — Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · Phase 2 · recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06779539 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06779539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing